Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07506473

Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial

Venous thromboembolism is a frequent issue in severe trauma patients. Guidelines for venous thromboembolism prevention include the use of pharmacological thromboprophylaxis, mainly with low-molecular-weight heparin, and/or mechanical thromboprophylaxis. However, a high incidence of venous thromboembolism is observed despite standard dose thromboprophylaxis (such as enoxaparin 40 mg once daily).

An increase of the dose of anticoagulants could improve thromboprophylaxis in trauma patients. To date, two randomised trials have assessed the effect of weight-based low-molecular-weight heparin dosing vs. fixed dose in trauma patients. These pilot studies did not demonstrate a statistical difference between groups although there was a trend in favour of a lower incidence of deep vein thromboses with the increased dose low-molecular-weight heparin prophylaxis. However, both studies included non-severe trauma patients and the second study focused only on deep vein thromboses. Other studies suggested that a superior-than-standard dose of low-molecular-weight heparin, sometimes

guided by the anti-Xa activity, decreases the incidence of venous thromboembolism in severe trauma without increasing bleeding events, but they were observational in nature.

The hypothesis of the HEPTRAUMA trial is that, in severe trauma patients, a thromboprophylaxis with intermediate dose low-molecular-weight heparin (twice the standard dose) decreases the incidence of major venous thromboembolism compared to standard dose.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Severe Trauma Patient Cardiovascular Diseases Embolism and Thrombosis Thromboembolism Vascular Diseases Venous Thromboembolism Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Angers, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All adult patients (age ≥18 years) admitted to an intensive care unit following trauma with an expected stay >48 hours and a planned administration of LMWH.
  • Affiliation to the French social security system or European (CEAM)

Exclusion criteria

  • Prehospital cardiac arrest
  • Hospital admission >72 hours
  • More than one dose of prophylactic anticoagulant already administered since trauma
  • Renal failure defined by creatinine clearance of 30 mL/min or less (Cockcroft-Gault formula)
  • Body weight >100 kg or <45 kg
  • Indication for therapeutic anticoagulation
  • Major known thrombophilia (e.g. antiphospholipid syndrome, antithrombin deficiency)
  • Constitutional bleeding disorder (haemophilia, von Willebrand disease, coagulation factor deficiency, platelet disorder).
  • Thrombocytopenia inferior to 50 G.L-1
  • History of heparin-induced thrombocytopenia
  • Study drug hypersensitivity
  • Limitation of life support, life expectancy ≤7 days or palliative care
  • Contraindication to the administration of anticoagulant according to the SPC (Active clinically significant bleeding or a condition associated with a high risk of bleeding, such as a recent haemorrhagic stroke, gastrointestinal ulcer, the presence of a malignant tumour at high risk of bleeding, recent brain, spinal or ophthalmological surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intrarachid or intracerebral vascular anomalies.)
  • pregnant or breastfeeding woman
  • Inclusion in another experimental trial
  • Protected person (art. L1121-5 to L1121-8 of the CSP or art. 31 to 35 of European regulation 536/2014)

Treatment and study plan

Enoxaparin standard dose

Drug

In the control group, patients will receive 1 injection of enoxaparin 4000 IU and 1 injection of placebo until day 14 or hospital discharge in the same form as enoxaparin (subcutaneous injection).

A placebo injection is administered as needed to maintain blinding and ensure the same number of injections as in the intermediate-dose arm.

Enoxaparin intermediate dose

Drug

In the experimental group, patients will receive 2 injections of enoxaparin 4000 IU until day 14 or hospital discharge.

Primary outcomes

  1. Composite of symptomatic deep vein thrombosis (DVT), proximal DVT, pulmonary embolism (PE).

    Time frame: Within 14 days following randomisation after severe trauma

    Effect of intermediate-dose versus standard-dose enoxaparin on the 14-day risk of major venous thromboembolism (symptomatic proximal DVT or PE) in adult patients with severe trauma eligible for pharmacologic thromboprophylaxis. Analyses will be conducted in the ITT population using a competing-risk approach (death before VTE considered as a competing event).

Secondary outcomes

  1. To evaluate the effect of intermediate versus standard dose low-molecular-weight heparin on the net clinical benefit combining major venous thromboembolism and major bleeding events

    Time frame: Within 14 days following randomisation

    Composite of major venous thromboembolism, as defined in the primary endpoint, and major bleedings, defined by (i) the need for a haemostatic invasive procedure because of bleeding, (ii) the need for interruption of prophylactic enoxaparin for ≥48 hours because of bleeding, or (iii) bleeding in a critical organ within 14 days following randomisation after a severe trauma

  2. To evaluate the effect of intermediate versus standard dose low-molecular-weight heparin on the individual components of the primary outcomethe incidence of major bleeding and clinically relevant non-major bleeding as per ISTH definition

    Time frame: Within 14 days following randomisation

    • Symptomatic DVT of the lower limb within 14 days following randomisation
    • Proximal DVT within 14 days following randomisation
    • Pulmonary embolism within 14 days following randomisation

  3. To evaluate the effect of intermediate versus standard dose LMWH on the incidence of major bleeding and clinically relevant non-major bleeding as per ISTH definition

    Time frame: During or within 48h of the last dose of study drug

    Major or clinically relevant non-major bleeding, as per ISTH definition, occurring during or within 48h of the last dose of study drug

  4. To evaluate the effect of intermediate versus standard dose LMWH on the incidence of red blood cell transfusions within 14 days following randomisation after severe trauma (or until hospital discharge)

    Time frame: Within 14 days following randomisation (or until hospital discharge)

    Number of red blood cell transfusions within 14 days following randomisation after severe trauma (or until hospital discharge)

  5. To evaluate the effect of intermediate versus standard dose LMWH on the incidence of major VTE and major bleeding at day 30 following randomisation after a severe trauma

    Time frame: At day 30 following randomisation

    Incidence of major VTE (as defined in the primary endpoint) and major bleeding (as per ISTH definition) at day 30 following randomisation after a severe trauma

  6. To evaluate the effect of intermediate versus standard dose LMWH on the incidence of deaths at day 30 following randomisation

    Time frame: At day 30 following randomisation

    Death at day 30 following randomisation after trauma

Study contacts

Contact information is provided by the study sponsor or research team.

Alexandre GODON

CONTACT

[email protected]

+33 4 76 76 75 75

Juliana BENY

CONTACT

[email protected]

+33 4 76 76 79 55

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Acronym: HEPTRAUMA

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Apr 1, 2026
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.